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ABSTRACT
BACKGROUND: Fentanyl congeners have been found to induce cough during
induction of general anesthesia. Studies of fentanyl and sufentanil have found inci-
dence rates of28% to 65% and 15%, respectively. However, no study has assessed the
occurrence of cough induced by remifentanil.
OBJECTIVE: The aim of this study was to assess the effect of equivalent doses of
fentanyl, sufentanil, and rernifentanil on cough,
METHODS: Patients rated American Society of Anesthesiologists class I or II
of either sex, aged 18 to 60 years, who were scheduled for elective abdominal surgery
with general anesthesia were randomly and equally assigned to 3 groups using a
computer-generated table of random numbers. The patients received equivalent doses
of fentanyl 2 pg/kg, sufentanil 0.2 pg/kg, or remifentanil 2 pg/kg via IV push. Vital
signs (systolic blood pressure [SBP}, heart rate [HR}, and oxygen saturation via pulse
oximetry [Sp02}) and the occurrence and severity of cough were recorded for 2 min-
utes after drug administration by an anesthesiologist who was blinded to the drug
treatment. The severity of cough was graded as none (0), mild 0-2), moderate (3-5),
or severe (>5).
RESULTS: A total of 315 Chinese patients (197 women, 118 men; mean [SD}
age, 37.9 [lOA} years) were approached for enrollment and assigned to 3 groups of
105 patients each; all patients completed the study protocol. The 3 treatment groups
were similar in terms of demographic characteristics and type of abdominal surgery. The
incidence of cough was significantly greater in the remifentanil group (57 [54.3%} pa-
tients) than in the fentanyl group (35 [33.3%}; P < 0.01) or the sufentanil group
(32 [30.5%}; P < 0.01). The severity of cough was significantly greater in the rerni-
fentanil group (severe, moderate, mild, none: 24, 7, 26, 48) than in the fentanyl (7,
9,19, 70; P < 0.01) or sufentanil group (4,2,26,73; P < 0.01). In all 3 groups, when
the patients coughed, significant increases were observed in their SBP (128 [l2}-
139 [l6} mm Hg; P < 0.01) and HR (74 [l0}-87 [l6} beats/min; P < 0.01). Within
2 minutes after drug administration, 62 patients (59%) in the remifentanil group
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experienced hypoxemia (Sp02 <90% ) necessitating manually assisted mask ventila-
tion, while no patients experienced hypoxemia in the fentanyl or sufentanil group.
Three patients (2.9%) in the remifentanil group experienced muscle rigidity and
deterioration of SBP, HR, and SpO'). No other adverse events were recorded.
CONCLUSION: Rernifenranil was associated with a significantly greater incidence
and severity of cough than equivalent doses of fentanyl or sufentanil. Fentanyl and
sufentanil appeared comparable in these Chinese patients undergoing abdominal surgery.
(Curr Ther Res Clin Exp. 2008;69:480-487) © 2008 Excerpta Medica Inc.
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INTRODUCTION
Coughing is undesirable in patients with some coexisnng conditions, including
increased intracranial pressure, open eye injury, dissecting aortic aneurysm, pneumo-
thorax, and reactive airway disease. 1Fentanyl and sufenranil have been associated with
general anesthesia-induced cough. The incidence of fentanyl-induced cough has been
found to vary from 28 % to 65 %.1--4 The incidence of sufentanil-induced cough was
reported to be 15% after a bolus of sufentanil 0.3 JIg/kg over 5 seconds.? However, a
search of MEDLINE (1956-August 2007) using the terms remifentanil, incidence, and
cough, coughing, or tussive effect yielded no results.
In an unpublished preliminary study that was intended to determine the necessary
data for sample size calculations in the present study, we observed that the incidence
of sufentanil-induced cough was 30 % after a bolus of sufentanil 0 .2 JIg/kg adminis-
tered via IV push and that remifentanil might also evoke cough. We designed a pro-
spective, randomized, double-blind study to compare the incidence and severity of
coug h induced by equivalent doses of fentanyl, sufentanil, and rernifentanil .
PATIENTS AND METHODS
This study was conducted at the Jinling Hospital, Nanjing University, Nanjing,
China, between August 2007 and March 2008. The study protocol was approved by
the ethics committee of Jinling Hospital. Written informed consent was obtained
from all patients before study enrollment.
Patients rated American Society of Anesthesiologists class I or II of either sex, aged
18 to 60 years, who were scheduled for elective abdominal surgery with general
anesthesia were eligible for the study. Exclusion criteria were as follows: weight >20%
above ideal; impaired kidney or liver function; the presence of a gastric tube; a history
of asthma, chronic cough, or smoking; upper respiratory tract infection in the previ-
ous 2 weeks; and recent treatment with angiotensin-converting enzyme inhibitors,
bronchodilators, or corticosteroids.
One investigator (J.-G.X.) evaluated all inclusion/exclusion criteria and random-
ized the patients to 1 of 3 groups using a computer-generated table of random numbers
to receive fentanyl (50 JIg/mL; Renfu Co. , Hubei, China), sufentanil (50 JIg/mL;
Renfu Co.), or remifentanil (1000 JIg/bottle; Renfu Co.). The same investigator was
responsible for drug preparation. The allocation sequences were contained in a set of
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sealed envelopes, and the other investigators and patients involved in the study were
blinded to treatment assignment.
Sufentanil and rernifenranil were diluted with normal saline to 10 mL and 20 mL ,
respectively, whereas fentanyl was not diluted. Each drug preparation was the same
volume and all were colorless and odorless. All administrations were conducted via
5-second IV push . By reducing the minimal alveolar concentration of isoflurane,
the potency ratios of fentanyl, sufentanil , and remifentanil were nearl y 1:10:16-9;
fentanyl 2 pg/kg (50 ug/rnl.), sufentanil 0.2 pg/kg (5 pg/rnl.), or remifentanil 2 pg/kg
(50 pg/rnl.) was admini stered via IV push.
No premedication was allowed. In the operating room, venous access to the median
cubital vein was established with a 20G IV cannula that was connected to a venous
transfusion tubing via a 3-way joint. Electrocardiogram and oxygen saturation via
pulse oximetry (Sp02) were monitored, and a radial artery cannula was inserted to
monitor blood pressure (BP). The mean (SD) vertical d istance between the drip bottle
and the median cubital vein was 90 (5) em. With the controller of the IV fluid run-
ning rate fully opened, the drug was administered at a relatively constant rate via IV
push within 5 seconds by an investigator a.-C.S.) who had been trained in controll ing
the administration rate. A stopwatch was used to monitor the time between drug
administration and the onset of coughing.
In an unpublished preliminary study of 90 patients using a 3-m inute observation
period, all coughing occurred within 1 minute after study drug administration, and a
decrease in Sp02 to <90% usually occurred within 2 minutes in 72% of patients in
the remifentanil group. When Sp02 decreased to <90% , manually-assisted ma sk
ventilation with pure oxyg en was to be applied immedi ately. Consequently, 2 minutes
was chosen as the observation period in the present study. Atropine 0.5 mg IV was
administered immediately if the heart rate (HR) was <50 beats/min. The primary
outcom e was the incidence of cough and the secondary outcome was the severity of
cough, which was graded as none (0), mild (1-2), moderate 0-5), or severe (>5 ).2,5
All evaluators were trained in the grading technique at the same time.
Systolic BP (SBP) , HR, and Sp02 were recorded before drug administration. The
lowest Sp02 within 2 minutes after drug administration was recorded in all patients;
and the highest SBP and HR within 2 minutes were recorded in patients who coughed.
Sp02 was also recorded when a patient required manually assisted mask ventilation.
STATISTICAL ANALYSIS
We conducted a preliminary study using the same protocol as the present study in
3 groups of 30 patients each . The results of the study were not published. Eleven
patients (37 %) in the fentanyl group, 9 (30 %) in the sufentanil group, and 16 (53%) in
the remifentanil group coughed. With an a = 0.05, 13 = 0.1 , maximal percentage =
55 % , and minimal percentage = 30% , this analysis suggested that 97 patients were
needed in each group. To allow for poss ible dropouts prior to study initiation, it was
determined that 105 patients would be enrolled in each group.
Values are reported as mean (SO), median (range), or number (%) . The binary vari-
ables, including the incidence of cough, were compared using the Fisher exact test
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with Bonferroni correction. Ranked variables (including the severity ofcough) or non-
normally distributed variables were compared using the Kruskal-Wallis H test fol-
lowed by the Dunn test for post hoc multiple comparisons. Normally distributed
variables were compared using I-way analysis of variance followed by the least signifi-
cant difference test or paired t test. P < 0.05 was considered statistically significant.
RESULTS
A total of 315 patients were approached for enrollment (197 women, 118 men; mean
[SD} age, 37.9 [lOA} years) and randomly assigned to 3 groups of 105 patients each.
The 3 treatment groups were similar in terms of demographic characteristics and type
of surgery (Table I). All the enrolled patients completed the study protocol.
The incidence ofcough was significantly greater in the remifentanil group (57 [54.3%})
than in the fentanyl group (35 [33.3%}; P < 0.01) or the sufentanil group (32
[30.5%}; P < 0.01). The severity of cough was significantly greater in the remi-
fentanil group (none, mild, moderate, severe: 48, 26, 7, 24, respectively) compared
with the fentanyl (70, 19, 9, 7; P < 0.01) or the sufentanil group (73, 26, 2, 4;
P < 0.01). The incidence and severity of cough between the fentanyl and the
sufentanil groups were not significantly different. The time to onset of cough for
the sufentanil group (24.0 [4.3} seconds) was significantly longer than that for
the fentanyl 09.7 [3.3}; P < 0.01) or remifentanil groups (18.6 [3.2}; P < 0.01)
(Table II).
In all 3 groups, when the patients coughed, significant increases occurred in their
SBP (128 [l2}-139 [l6} mm Hg; P < 0.01) and HR (74 [l0}-87 [l6} beats/min;
P < 0.01).
Median (range) Sp02 decreased significantly after drug administration in all 3 groups
(remifentanil, 8% [l-1O}; fentanyl, 2% [0-6}; sufentanil, 3% [0-8}; all, P <
Table I. Baseline demographic and clinical characteristics of the study patients (N =
315).*
Fentanyl Sufentanil Remifentanil
Characteristic (n = 105) (n = 105) (n = 105)
Age, mean (SO), y 37.6 (10.3) 39.1 (10.0) 37.2 (10.9)
Sex, no. (%)
Female 64 (61) 65 (62) 68 (65)
Male 41 (39) 40 (38) 37 (35)
Height, mean (SO), cm 166.5 (7.5) 165.6 (7.2) 164.7 (6.9)
Weight, mean (SO), kg 62.0 (7.6) 61.2 (7.3) 60.1 (8.5)
Abdominal surgery, no. (%)
Lower 66 (63) 59 (56) 62 (59)
Upper 39 (37) 46 (44) 43 (41)
*No significant between-group differences were found.
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Table II. Incidence, severity, and time to onset of cough after receiving a single admin-
istration of fentanyl, sufentanll, or remifentanll (N =315).
Fentanyl Sufentanil Remifentanil
Characteristic (n = 105) (n = 105) (n = 105)
Incidence, no. (%) 35 (33.3) 32 (30.5) 57 (54.3)*
Severity, no. (%)t
None 70 (66.7) 73 (69.5) 48 (45.7)
Mild 19 (18.1) 26 (24.8) 26 (24 .8)
Moderate 9 (8.6) 2 (1.9) 7 (6.7)
Severe 7 (6.7) 4 (3.8) 24 (22.9)*
Time to onset, mean (SD), s 19.7 (3.3) 24.0 (4.3)1' 18.6 (3.2)
*p < 0.01 versus the fentanyl and sufentanil groups.
tSeverity was based on the follow ing score scale: none, 0; mild, 1 to 2: moderate, 3 to 5; severe, >5.2.5
t p < 0.01 versus the fentanyl and remifentanil groups.
0 .01). The decrease was significantly greater in the remifentanil group compared with
the fentanyl and sufentanil groups (both, P < 0.01) (Table III). Within 2 minutes after
drug administration, 62 patients (59 %) in rhe remifentanil group experienced hypox-
emia (Sp02 <90%) that necessirared manually-assisted mask ventilation; no patients in
the fentanyl or sufentanil group experienced hypoxemia.
Three patients in the remifentanil group experienced noticeable muscle rigidity
but did not cough. One of them, a 42-year-old female (baseline height, 165 em ;
weight, 65 kg; BP, 116/6 3 mm Hg; HR, 72 beats/min; and Sp02' 99%) experienced
bradycardia. One minute after rernifentanil injection, her BP, HR, and Sp02decreased
to 85 /50 mm Hg, 4 5 beats/min, and 90 %, respectively. Atropine 0.5 mg IV was
administered; however, manually-assisted mask ventilation was difficult, possibly due
to muscle rigidity. Rocuronium bromide 50 mg was administered immediately, and
BP, HR, and Sp02 recovered 1 minute later. The other 2 patients (48-year-old male,
169 em, 70 kg; 30-year-old female, 160 em, 60 kg) experienced increases in BP
(150/76-207/101 and 131/66-176/89 mm Hg, respecrively) and HR (85-108 and
Table III. Median (range) oxygen saturation via pulse oximetry (Sp02) at baseline and
after receiving fentanyl, sufentanll, or remifentanll (N = 315).
Fentanyl Sufentanil Remifentanil
Characteristic (n = 105) (n = 105) (n = 105)
Baseline Sp02' % 99 (97-100) 99 (97-100) 99 (97-100)
Lowest Sp02' % 97 (92-100)* 96 (91-100)* 90 (90-99)*t
Decrease in Sp02' % 2 (0-6) 3 (0-8) 8 (1-10)t
*p < 0.01 versus baseline .
t p < 0.01 versus the fentanyl and sufentanil groups .
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70-89 beats/min) and a decrease in SpOz (100%-95% and 97%-91 %). No other
adverse events were recorded.
DISCUSSION
Various mechanisms have been proposed to explain fentanyl-induced cough. A pul-
monary chemo reflex mediated by either vagal C-fiber receptors in close proximity to
pulmonary vessels 6 ,10,11 (juxtacapillary receptors) or by irritant receptors (rapidly
adapting receptors) has been suggested.i-" Opioid-induced histamine releasel? and
muscle rigidity leading to sudden adduction of the vocal cords or supraglottic ob-
struction by soft rissuel> have also been suggested. These mechanisms might explain
why fentanyl congeners are associated with cough in the present study. However, the
explanation for the significantly longer time to onset of sufentanil-induced cough
remains unclear.
In one study by Agarwal et al,z fentanyl 2 pg/kg administered via a peripheral
venous catheter over a period of 5 seconds elicited cough in 28% of patients under-
going elective laparoscopic cholecystectomy. Pandey et al 14 found that 35% ofelective
surgery patients coughed after receiving fentanyl 3 pg/kg' through a peripheral venous
catheter. Lin et all observed a 65% incidence of cough in elective surgery patients
following administration of fentanyl 2.5 j1g/kg IV via a freely running peripheral
venous catheter within 2 seconds. In the present study, the incidence of fentanyl-
induced cough was 33%. Different doses, administration routes, and administration
rate might explain the discrepancy in the incidence of cough between these studies.
In another study by Agarwal et al,5 sufentanil 0.3 pg/kg administered via a peripheral
catheter on the dorsum of the hand over 5 seconds was associated with cough in 15% of
the patients and the severity of sufentanil-induced cough was significantly less
than that of fentanyl (P = 0.039). However, we found the incidence of cough with
sufentanil was 30% and the severity of cough in the sufenranil group was similar to
that of the fentanyl group. The differing results between the 2 studies might be due
to differences in doses, concentrations, administration routes, administration rate, sam-
ple size, or race; whether the drugs were diluted with normal saline or water prior to
injection; and whether or not the patients were premedicated.
Coughing is associated with acute increases in BP, HR, and intracranial, intraocu-
lar, and intra-abdominal pressure.? In the present study, coughing was associated with
increases in BP and HR. SpOz decreased after drug administration in each group, with
the greatest SpO, decrease occurring in the rernifentanil group. The greatest effect
occurred with remifentanil at -1.3 minures.l? while the greatest effect with fentanyl
was at 3.6 minutes and with sufenranil at 5.6 minures.l?
Rernifenranil was reported to induce tonic-clonic activity in an otherwise healthy
adult.l? In the present study, 3 patients in the rernifenranil group had muscle rigidity.
Intravenous administration of rernifenranil has been associated with decreases in BP,
HR, carbon monoxide, and myocardial contractility. 18,19 In the present study, 1 patient
had significant bradycardia and required treatment with atropine, and 2 patients had
increased BP and HR and decreased SpOz' Thomson et alzo reported that 10% of the
patients with an intravenous administration of fentanyl 50 to 100 pg/kg for anesthesia
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induction experienced hyperdynamic cardiovascular effects due to activation of central
sympathetic nerves. Because IV push administration of rernifentanil might elicit these
severe adverse events, such as muscle rigidity or myocardial contractility, it should be
used cautiously or avoided in clinical practice. Therefore, though we performed the
present study using sufficient safety monitoring, the use ofIV push administration of
rernifentanil was a major limitation in the study protocol. Further studies are needed
to explore the mechanisms of the differences in the incidence and severity of cough
among fentanyl congeners.
CONCL.USION
Remifentanil was associated with a greater incidence and severity of cough than
fentanyl or sufentanil, while sufentanil and fentanyl appeared comparable in this
study in patients undergoing abdominal surgery.
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